• EFL079 - Incidental Physical Activity and the Risk for Type 2 Diabetes
    Nov 19 2026

    How should we think about incidental physical activity in lowering the risk of type 2 diabetes? Hear more in this episode!

    For our 79th episode, we review a recent Journal of Clinical Endocrinology & Metabolism (JCEM) article on incidental physical activity, the everyday movement outside of structured exercise. Many patients now track this activity with wearable devices, and clinicians often aren't sure what to do with that data. The study used wrist accelerometer data from nearly 23,000 UK adults who reported that they don't exercise. It found that just a few minutes a day of vigorous incidental activity was linked to a lower risk of type 2 diabetes. The findings also question the guideline assumption that 1 minute of vigorous activity equals 2 minutes of moderate activity.

    Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University talks with regular contributor Diana Soliman, MD, from the University of Miami, and guest expert Jane Reusch, MD, from the University of Colorado. They discuss a study by Sabag et al., published online in September 2026 in JCEM titled, "The dose-response association between wearables-quantified incidental physical activity and type 2 diabetes: a prospective cohort study."

    Read the article: https://doi.org/10.1210/clinem/dgag316

    Mehr anzeigen Weniger anzeigen
    35 Min.
  • EFL078 - SGLT1 Inhibition for the Treatment of Post-Bariatric Hypoglycemia
    Oct 22 2026

    For our 78th episode, we review a recent Journal of the Endocrine Society (JES) article reporting results from a Phase 2, single-dose trial of an SGLT1 inhibitor for post-bariatric hypoglycemia. This condition can be particularly difficult to diagnose and manage, and current treatments are not uniformly effective or well tolerated, with no FDA-approved therapy currently available. The study explores whether targeting intestinal glucose absorption could offer a new oral treatment option, while raising important questions about patient selection, clinically meaningful outcomes, and what a larger Phase 3 trial will need to demonstrate. Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University talks with regular contributor Steven D. Wittlin, MD, from the University of Rochester Medical Center, and guest expert Sangeeta Kashyap from Weill Cornell Health. They discuss a study by Lawler et al., published in the August 2026 issue of JES titled, “A single dose trial of mizagliflozin for the treatment of postbariatric hypoglycemia.”

    Mehr anzeigen Weniger anzeigen
    35 Min.
  • EFL077 - Inflammation vs. Immune-System Dysfunction in PCOS
    Sep 18 2026

    For our 77th episode, we discuss a study in the Journal of Clinical Endocrinology & Metabolism investigating the role of immune signaling in polycystic ovary syndrome (PCOS), now renamed polyendocrine metabolic ovarian syndrome (PMOS). Using a multiracial case-control design, the authors examined whether PCOS is characterized by chronic inflammation or whether immune dysregulation plays a more central role in its pathophysiology.

    Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt Health, is joined by regular contributor Anna Goldman, MD, from Harvard Medical School, Brigham and Women's Hospital, and Atrius Health, along with guest expert Corrine Welt, MD, Chief of Endocrinology at the University of Utah, to discuss "Multiracial Cytokine Profiling Reveals Immune Dysregulation not Chronic Inflammation in Polycystic Ovary Syndrome." Together, they explore the implications of the syndrome's recent name change, review the study's unexpected findings of lower circulating inflammatory markers in women with PCOS, and discuss the challenges of disentangling the effects of adiposity, metabolism, and immune function. The conversation highlights what these results reveal about the evolving understanding of PCOS and whether they have implications for current clinical practice.

    Mehr anzeigen Weniger anzeigen
    28 Min.
  • EFL076 - Pregnancy Outcomes in PCOS and GDM
    Aug 25 2026

    For our 76th episode, we discuss a recent Journal of Clinical Endocrinology & Metabolism secondary analysis examining pregnancy outcomes among women with polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM). Drawing on data from the DiGest randomized clinical trial, the study explores whether PCOS influences maternal and neonatal outcomes and whether a reduced-calorie dietary intervention benefits women with these coexisting metabolic conditions.

    Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University, is joined by regular contributor Alison Myers, MD, from Albert Einstein College of Medicine and Montefiore Medical Center, along with guest expert Ellen Seely, MD, from Brigham and Women's Hospital and Harvard Medical School, to discuss "Association between polycystic ovary syndrome and pregnancy outcomes in GDM: A secondary analysis of the DiGest trial" . Together, they examine the challenges of interpreting secondary analyses, the role of PCOS in pregnancy risk, the potential effects of dietary intervention in gestational diabetes, and what these findings mean for the clinical care of women with PCOS and GDM.

    Mehr anzeigen Weniger anzeigen
    47 Min.
  • EFL075 - Methimazole Titration and Initial Disease Severity in Graves' Disease
    Jul 16 2026

    How does the severity of Graves disease at presentation affect subsequent methimazole dose titration? Find out more in this month's episode!

    For our 75th episode, we review a forthcoming Journal of Clinical Endocrinology & Metabolism study examining whether the severity of Graves disease at presentation influences methimazole titration and treatment management. Drawing on a retrospective longitudinal cohort of 152 patients, the study provides a real-world look at antithyroid drug dosing and monitoring practices.

    Host Chase Hendrickson, MD, MPH, MMHC, from Vanderbilt University, is joined by new regular contributor Jonea Lim, MD, from the University of Oklahoma, and guest expert Elizabeth Pearce, MD, MSc, from Boston University. Together, they discuss “Initial disease severity and methimazole titration for Graves' disease: a retrospective longitudinal cohort study” and explore its implications for the clinical management of Graves disease.

    Want to learn more? Visit the Episode 75 webpage for additional resources and information about our guests and host.

    Mehr anzeigen Weniger anzeigen
    37 Min.
  • EFL074 - Taking Levothyroxine Fasting vs. With Breakfast
    Jun 18 2026

    For our 74th episode, recorded live at ENDO 2026 in Chicago, we review a recent JCEM study that addresses a common clinical question: does levothyroxine need to be taken on an empty stomach?

    This randomized clinical trial evaluates a dose-adjusted, non-fasting regimen and finds that a 15% increase with breakfast ingestion achieves TSH stability similar to that with standard fasting dosing. The results also suggest potential improvements in adherence and patient-reported well-being, while highlighting variability in dose adjustments and limitations in generalizability.

    Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University, is joined by regular contributor Andy Crawford, MD, from Dartmouth-Hitchcock Medical Center, and guest expert Matt Edelson, MD, from the University of Chicago. Together, they discuss “Fasting versus non-fasting dose-adjusted levothyroxine ingestion in hypothyroidism,” published in the April 2026 issue of JCEM, and consider how these findings may inform patient-centered approaches to medication timing and management.

    Mehr anzeigen Weniger anzeigen
    33 Min.
  • EFL073 - Infrequent Zoledronate in Low Fracture Risk
    May 21 2026

    For our 73rd episode and the start of the seventh season, we review a recent study examining the long-term anti-fracture efficacy of infrequent zoledronate dosing in women with osteopenia. While current clinical approaches typically focus on treating individuals at higher fracture risk, this study explores whether earlier intervention in lower-risk populations may help reduce fracture risk over time.

    This secondary analysis of a randomized clinical trial evaluates the effects of zoledronate administered at extended intervals, with outcomes assessed over a 10-year period. The findings suggest that infrequent dosing may be associated with meaningful reductions in vertebral, major osteoporotic, and overall fracture risk, particularly in the later years of follow-up. The study also examines how fracture risk relates to baseline risk factors and changes in bone mineral density, raising questions about the role of routine monitoring and the timing of preventive therapy.

    Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University, talks with regular contributor Amal Shibli Rahhal, MD, from the University of Iowa, and guest expert Thomas Weber, MD, from Duke Health. Together, they discuss “Anti-fracture efficacy of 5 or 10 yearly zoledronate in women aged 50 to 60 years,” published in the April 2026 issue of JCEM, and consider how these findings may inform decisions around early treatment strategies, risk assessment, and long-term fracture prevention in clinical practice.

    Mehr anzeigen Weniger anzeigen
    38 Min.
  • EFL072 - Pre-Operative Use of Mineralocorticoid-Receptor Antagonists in Primary Aldosteronism
    Apr 22 2026

    For our 72nd episode and the final episode of the sixth season, we review a recent study examining the perioperative medical management of primary aldosteronism, with a focus on the use of mineralocorticoid receptor antagonists before adrenalectomy. Primary aldosteronism is increasingly recognized as a common and clinically important cause of secondary hypertension, yet questions remain about optimal preoperative treatment strategies. This study explores whether pretreatment with mineralocorticoid receptor antagonists influences postoperative outcomes and longer‑term biochemical cure in patients undergoing surgery.

    Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University, talks with regular contributor Salila Kurra, MD, from Columbia University, and guest expert Jun Yang, MD, PhD, from Monash Health in Melbourne, Australia. Together, they discuss "Mineralocorticoid Receptor Antagonist Pre-Adrenalectomy in Primary Aldosteronism," published in the April 2026 issue of JCEM, and consider how these findings may inform perioperative management and surgical decision-making in clinical practice.

    Mehr anzeigen Weniger anzeigen
    44 Min.